Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, has historically presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, can lead to exceptional, durable responses (when the tumor substantially shrinks for a very long period of time) for some patients with mccRRC, allowing them to live longer with a better quality of life. However, the molecular reasons behind these exceptional responses have not been well defined.
Go to Source
Author: